| 吴魏芹,卢凯华,张梅玲.盐酸埃克替尼治疗晚期非小细胞肺癌的临床观察[J].中国肿瘤,2013,22(6):497-501. |
| 盐酸埃克替尼治疗晚期非小细胞肺癌的临床观察 |
| Clinical Observation of Icotinib Hydrochloride in the Treatment for Advanced Non-small Cell Lung Cancer |
| 投稿时间：2013-02-12 |
| DOI：10.11735/j.issn.1004-0242.2013.06.A201304133 |
|
 |
| 中文关键词: 盐酸埃克替尼 非小细胞肺癌 靶向治疗 |
| 英文关键词:icotinib hydrochloride NSCLC targeted therapy |
| 基金项目: |
|
| 摘要点击次数: 2678 |
| 全文下载次数: 1152 |
| 中文摘要: |
| 摘 要：［目的］ 探讨盐酸埃克替尼治疗晚期非小细胞肺癌（NSCLC）的临床疗效及安全性。 ［方法］ 对2011年9月至2012年9月间收治的42例晚期NSCLC患者进行随访观察，治疗方案为口服盐酸埃克替尼，125mg/次，3次/d，评价其近期和远期疗效以及不良反应。［结果］ 全组42例患者用药1个周期后，部分缓解11例，疾病稳定22例，疾病进展9例，客观有效率26.2%，疾病控制率78.6%。不良反应总发生率为52.4%，主要为皮疹（23.8%）、皮肤瘙痒（14.3%）及腹泻（9.5%）。近期疗效与患者性别、病理类型相关（P＜0.05）。PFS与患者性别、病理类型、ECOG评分相关，差异有统计学意义（P＜0.05）。［结论］ 盐酸埃克替尼治疗晚期NSCLC疗效肯定，且毒性低、安全性高、耐受性好，为晚期NSCLC患者的新选择。 |
| 英文摘要: |
| Abstract:［Purpose］ To evaluate the efficacy and toxicities of icotinib in 42 patients with advanced NSCLC. ［Methods］ Forty-two patients with advanced NSCLC were enrolled from September 2011 to September 2012. Patients were treated with icotinib(125mg，three times a day). The short-term response，long-term response，toxicity and quality of life were evaluated. ［Results］ Among the 42 patients，11 cases were partial response(PR); 22 cases，stable disease(SD) and 9 cases，progression disease(PD).The objective response rate(ORR) was 26.2% and disease control rate(DCR) was 78.6%. The overall incidence rate of toxicity was 52.4%，including rash(23.8%)，dry skin(14.3%)，and diarrhea (9.5%). Short-term response correlated with pathological type and gender (P＜0.05). Long-term response correlated with pathological type，gender and ECOG scores (P<0.05). ［Conclusion］ Icotinib is effective in the treatment for advanced NSCLC，with low toxicity，good safety and tolerability. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |